Replies to post #40877 on Biotech Values

[drbio45]

hey red,

happy new year, I mentioned here months ago that the company would have to raise money and it probably wouldn't be on favorable terms. There was a best favored nations status in the last deal so those buyers get the cheaper price.

Sometimes if you think the drug is valuable it pays to get a large raise done so you have the money to find out.

I owned conjuchem at over a dollar because I liked the their once weekly glp-1 data. Then the did a raise of over a hundred million at 65 cents canadian which was over 35 cents below the closing price the prior day because the raise was so large. it sucked but i got into the deal because it also came with 5o percent warrant coverage.

conjuchem cjb.to now has over 300 fully diluted shares but if amlyn can have a market cap of over 4 billion dollars with over half of its value for the LAR then conjuchem is cheap at 90 cents canadian, because their data looks better but is about a year behind in development.

sometimes you need to bite the bullet if you believe in the technology. I don't know anything about adh's technology